HNW
CYTK icon

High Note Wealth’s Cytokinetics CYTK Stock Holding History

High Note Wealth’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Hold
118
– – ﹤0.01% 405
2026
Q1 		$7.78K Hold
118
– – ﹤0.01% 417
2025
Q4 		$7.5K Sell
118
-13
-10% -$809 ﹤0.01% 383
2025
Q3 		$7.2K Buy
+131
New +$5.4K ﹤0.01% 364
2025
Q2 		– Sell
-79
Closed -$3.17K – 907
2025
Q1 		$3.17K Buy
79
+48
+155% +$2.21K ﹤0.01% 578
2024
Q4 		$1.46K Buy
+31
New +$1.61K ﹤0.01% 732

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

High Note Wealth's CYTK Position: Q2 2026 in Review

High Note Wealth held its Cytokinetics (CYTK) position steady in Q2 2026 at 118 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

High Note Wealth first reported a position in CYTK in Q4 2024 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • High Note Wealth held 118 shares of Cytokinetics worth $10.1K as of Q2 2026.
  • High Note Wealth left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of High Note Wealth's portfolio in Q2 2026, its #405 holding.
  • High Note Wealth first reported a position in Cytokinetics in Q4 2024 and has held it in 6 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on High Note Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.